Skip to main content
OpenTrials
Completed

NCT Number: NCT03386864

Metabolic Determinants of Cardiac Function

Assessment of cardiac energy metabolism in patients with impaired glucose tolerance

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

German Diabetes Center

Düsseldorf, North Rhine-Westphalia, 40223, Germany

About this study

Insulin resistance, hepatocellular lipids (HCL) and plasma concentrations of free fatty acids (FFA) are predictors of heart failure, the leading cause of mortality in patients suffering from type 2 diabetes mellitus (T2DM). Epidemiological data suggest that diabetic cardiomyopathy (DC) presents as ventricular dysfunction in patients with T2DM independent of coronary artery disease. The underlying cellular mechanisms are poorly understood. Reduced mitochondrial activity and insulin resistance of skeletal muscle relates to liver steatosis, possibly due to higher substrate flux to the liver. High oxidation rates in the liver result in oxidative stress, damage of mitochondria and apoptosis. The investigators hypothesize that (i) HCL and impaired liver energy metabolism correlate with ventricular dysfunction, (ii) impaired glucose uptake and mitochondrial capacity in skeletal muscle relates to enhanced oxidative capacity, oxidative stress and lipid deposition in heart tissue (iii) reduced myocardial oxidative capacity limits recovery of myocardial function in patients with acute heart failure.

The investigators aim to assess (i) liver energy metabolism and heart function, (ii) respiration and lipid metabolites in skeletal muscle and heart tissue in humans with advanced heart failure and (iii) the prognostic impact of these factors in humans with acute heart failure.

This study will improve the understanding of mechanisms underlying the development of DC and the identification of patients at risk for poor outcome in heart failure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥ 20 and ≤85 years
  • myocardial biopsy for medical reason

Exclusion criteria

  • acute infection
  • autoimmune disease
  • pregnancy
  • cancer

Treatment and study plan

Primary outcomes

  1. mitochondrial oxygen flux

    Time frame: Up to 36 months

    measured using high resolution respirometry. Unit: pmol/(s*mg)

Sponsors and collaborators

Lead sponsor

German Diabetes Center

Other

Collaborators

  • Heinrich-Heine University, Duesseldorf

Registry information

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Dec 29, 2017
Registry last updated
Aug 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.